2001
Platelet PlA2 polymorphism enhances risk of neurocognitive decline after cardiopulmonary bypass
Mathew J, Rinder C, Howe J, Fontes M, Crouch J, Newman M, Phillips-Bute B, Smith B, Group T. Platelet PlA2 polymorphism enhances risk of neurocognitive decline after cardiopulmonary bypass. The Annals Of Thoracic Surgery 2001, 71: 663-666. PMID: 11235724, DOI: 10.1016/s0003-4975(00)02335-3.Peer-Reviewed Original ResearchConceptsMini-Mental State ExaminationPlA1/A1PlA1/A2Cardiopulmonary bypassNeurocognitive declinePlA2 polymorphismPlatelet GPIIIaState ExaminationBaseline Mini-Mental State ExaminationGreater neurocognitive declineProthrombotic genetic factorsPostoperative day 4Prothrombotic risk factorsEmbolic insultFrequent complicationPlA2 allelePlaque embolizationLocal thrombosisRisk factorsThrombotic processCardiovascular settingsPlA2 genotypeNeurocognitive changesDay 4Multivariate analysis
1999
Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass
Fitch J, Rollins S, Matis L, Alford B, Aranki S, Collard C, Dewar M, Elefteriades J, Hines R, Kopf G, Kraker P, Li L, O’Hara R, Rinder C, Rinder H, Shaw R, Smith B, Stahl G, Shernan S. Pharmacology and Biological Efficacy of a Recombinant, Humanized, Single-Chain Antibody C5 Complement Inhibitor in Patients Undergoing Coronary Artery Bypass Graft Surgery With Cardiopulmonary Bypass. Circulation 1999, 100: 2499-2506. PMID: 10604887, DOI: 10.1161/01.cir.100.25.2499.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedBlood Loss, SurgicalCardiopulmonary BypassCognition DisordersComplement ActivationComplement C5Complement Membrane Attack ComplexCoronary Artery BypassCoronary DiseaseCreatine KinaseHumansInflammationIsoenzymesMiddle AgedMyocardial Reperfusion InjuryPostoperative ComplicationsProspective StudiesPsychological TestsSingle-Chain AntibodiesConceptsMini-Mental State ExaminationPathological complement activationCardiopulmonary bypassBlood lossMyocardial injuryC5 inhibitionTissue injuryCoronary artery bypass graft surgeryComplement inhibitorsArtery bypass graft surgeryComplement activationCognitive deficitsSingle-chain antibodyC5 complement inhibitorNew cognitive deficitsSignificant dose-dependent inhibitionBypass graft surgeryPostoperative blood lossPostoperative myocardial injurySystemic inflammatory responseComplement-mediated inflammationLeukocyte CD11b expressionNovel therapeutic strategiesComplement hemolytic activityDose-dependent fashion